NeuroSense
Therapeutics
New Hope on The Horizon
About
NeuroSense
NeuroSense was born with the intent to answer the huge unmet need of patients with amyotrophic lateral sclerosis (ALS) with the understanding that this devastating disease must be addressed from a new perspective.
NeuroSense Therapeutics is a clinical-stage drug development company, advancing a groundbreaking treatment for people living with ALS, as well as other neurodegenerative diseases. We are focused on creating combined therapeutic strategies, targeting the multiple pertinent mechanisms in these complex diseases.
About
NeuroSense
NeuroSense Therapeutics is a late-stage clinical biotech company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases.
NeuroSense was founded in 2017 by Alon Ben-Noon, following a chance encounter with Shay Rishoni, a person living with ALS. Alon was inspired by Shay, who had served as the CEO of a non-profit organization for ALS. This pivotal meeting led Alon to team up with world-renowned scientists and biotech professionals to carry out research and develop an effective drug for ALS, eventually establishing NeuroSense.
“Never believe that a few caring people can’t change the world.
For, indeed, that’s all who ever have.”
— Margaret Mead
Novel Therapy
Neurodegenerative diseases are complex with many underlying pathologies. Our goal is to create combined therapies targeting the multiple pathways affected by these conditions. Therefore, we research the diseases’ core mechanisms and then develop combined therapies to target them in an optimal way and synergistic manner.
Expedited Development
NeuroSense is developing PrimeC, a unique formulation of a fixed-dose combination drug comprising ciprofloxacin and celecoxib, for amyotrophic lateral sclerosis (ALS). PrimeC has demonstrated efficacy, safety, and tolerability in PARADIGM, a phase 2b clinical trial in people living with ALS. The successful study highlighted PrimeC’s significant impact on slowing down disease progression and increasing survival rates. PrimeC has a strong patent estate, with coverage out to 2042, and has been granted orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). NeuroSense is now preparing to commence a pivotal Phase 3 clinical study, in parallel to exploring commercial approval from Health Canada.
Recent Updates
Join Our Newsletter
